» Articles » PMID: 18398104

Mechanism of Synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation

Overview
Specialty Oncology
Date 2008 Apr 10
PMID 18398104
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: ABT-737 is a pan-Bcl-2 inhibitor that has a wide range of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts. A relationship between expression of myeloid cell leukemia 1 (Mcl-1), an antiapoptotic member of the Bcl-2 family of proteins, and resistance to ABT-737 has been reported for various cancers. The synthetic cytotoxic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) is known to generate reactive oxygen species (ROS), and ROS have been shown to activate c-Jun kinase (JNK), which in turn phosphorylates and inhibits Mcl-1. Thus, we investigated whether 4-HPR-mediated inactivation of Mcl-1 could act synergistically with ABT-737 to promote leukemia cell death.

Methods: Cytotoxicity was determined using the fluorescence-based DIMSCAN assay. Synergy was defined as a combination index (CIN) less than 1. The expression of Bcl-2 family messenger RNAs was measured by real-time reverse transcription-polymerase chain reaction, and caspase activity was measured enzymatically. Changes in Bcl-2 family proteins and release of mitochondrial cytochrome c were detected by immunoblotting. ROS, apoptosis, mitochondrial membrane depolarization, and phospho-JNK were measured by flow cytometry. Gene silencing was by small interfering RNA (siRNA). All statistical tests were two-sided.

Results: ABT-737 decreased Mcl-1 protein expression in ABT-737-sensitive ALL cell lines but not in ABT-737-resistant lines. Using the antioxidant ascorbic acid and siRNA-mediated knockdown of JNK, we showed that 4-HPR decreased Mcl-1 via ROS generation (that phosphorylates JNK) in ABT-737-resistant cell lines. Combining ABT-737 with 4-HPR enhanced the mitochondrial apoptotic cascade (percentage of cells with depolarized mitochondrial membrane at 6 hours, ABT-737 vs ABT-737 plus 4-HPR: 24.5% vs 45.5%, difference = 20.1%, 95% CI = 18.9% to 13.9%; P < .001) and caused caspase-dependent, synergistic multilog cytotoxicity in all seven ALL cell lines examined (mean CIN = 0.57, 95% CI = 0.37 to 0.87), with minimal cytotoxicity for normal lymphocytes.

Conclusions: An increase of Mcl-1 protein in response to ABT-737 is one mechanism of ABT-737 resistance that can be overcome by 4-HPR, resulting in synergistic cytotoxicity of ABT-737 combined with 4-HPR in ALL cell lines.

Citing Articles

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent Activities in Mouse Models of Hematological and Solid Tumors.

Tarr J, Salovich J, Aichinger M, Jeon K, Veerasamy N, Sensintaffar J J Med Chem. 2024; 67(16):14370-14393.

PMID: 39102508 PMC: 11345828. DOI: 10.1021/acs.jmedchem.4c01188.


Nano-fenretinide demonstrates remarkable activity in acute promyeloid leukemia cells.

Farruggia G, Anconelli L, Galassi L, Voltattorni M, Rossi M, Lodeserto P Sci Rep. 2024; 14(1):13737.

PMID: 38877119 PMC: 11178801. DOI: 10.1038/s41598-024-64629-w.


Small molecules targeting protein-protein interactions for cancer therapy.

Wu D, Li Y, Zheng L, Xiao H, Ouyang L, Wang G Acta Pharm Sin B. 2023; 13(10):4060-4088.

PMID: 37799384 PMC: 10547922. DOI: 10.1016/j.apsb.2023.05.035.


Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

Jin P, Jiang J, Zhou L, Huang Z, Nice E, Huang C J Hematol Oncol. 2022; 15(1):97.

PMID: 35851420 PMC: 9290242. DOI: 10.1186/s13045-022-01313-4.


Cell-Permeable Bak BH3 Peptide Induces Chemosensitization of Hematologic Malignant Cells.

Ugarte-Alvarez O, Munoz-Lopez P, Moreno-Vargas L, Prada-Gracia D, Mateos-Chavez A, Becerra-Baez E J Oncol. 2020; 2020:2679046.

PMID: 33312200 PMC: 7721494. DOI: 10.1155/2020/2679046.